Enteral formulation: low in fat and containing protein hydrolysates
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsR. Armour Forse, Stacey J. Bell, Peter Burke
Life of this patent
Estimating the term…
Abstract
An improved enteral formulation that is low in fat and contains protein hydrolysates has been developed. The osmolality of the formulation is controlled to be below 500 mOs/kg H.sub.2 O, preferably about 300 mOs/kg H.sub.2 O. In a preferred embodiment, the formulation contains corn starch to control blood glucose levels. This formulation is particularly useful for treatment of critically ill patients and in minimizing a risk of pulmonary aspiration and/or gastrointestinal dysfunction in such patients.
Claims17
A method of treating critically ill patients comprising the step of administering an enteral formulation to said patient, said enteral formulation comprising about 2-4g/l fat, about 50-100 g/l protein hydrolysate, about 160-250 g/l carbohydrate, and water,
- whereby the osmolality of said enteral formulation is controlled to be 250-500 mOs/kg H.sub.2 O.
A method of controlling blood sugar levels in patients comprising administering an enteral formulation to said patients, said enteral formulation comprising about 2-4g/l fat, about 50-100 g/l a protein hydrolysate, about 160-250 g/l carbohydrate, wherein about 3-6 g/l of said carbohydrate are from corn starch, and water,
- whereby the osmolality of said enteral formulation is controlled to be 250-500 mOs/kg H.sub.2 O.
Dependencies are inferred from the claim text.